CMS选定礼来Trulicity和吉利德Biktarvy进入第三轮Medicare价格谈判。
CMS picks Lilly’s Trulicity, Gilead's Biktarvy for third round of Medicare negotiations
生物技术与制药领域的最新动态
CMS picks Lilly’s Trulicity, Gilead's Biktarvy for third round of Medicare negotiations
Hospitals could earn more for buying US-made drugs, CMS proposes
Cardiff execs depart as company drops mixed Phase 2 data
UnitedHealth projects lower revenue in 2026 as it resets its business
FDA lifts hold on one of two Phase 3 gene editing studies by Intellia
Insilico’s latest deal is a $120M cardiometabolic drug discovery pact with Qilu Pharma
AstraZeneca ends work on cardio drug; Lisata and Qilu terminate deal
Virtual women’s health company Wisp buys TBD Health
Boehringer Ingelheim gets an IBD bispecific from Shanghai-based Simcere
UK-US biotech investor Epidarex raises $145M for fourth fund
IRA drug pricing petitions pile up at the Supreme Court
Ex-CytoDyn CEO sentenced to 30 months for pump-and-dump scheme
Catalent plans to close Belgium cell therapy site
Sarepta touts three-year Duchenne gene therapy data after patient deaths
Genyro licences DNA builder from Caltech; Dizal targets Hong Kong listing
UK medicines agency seized 20M illegal drugs last year, including GLP-1s
Genmab halts enrollment for cancer drug from ProfoundBio buyout
First-movers respond to herding; BioMarin vets start new biotech; GSK buys RAPT Therapeutics; and more
Novo's Wegovy pill off to a solid start after just two weeks on market
EU kicks off one-year pilot to expedite multinational trials